UNSPSC 51182064: Prasterone sodium sulfate

This classification denotes a therapeutic androgen with the molecular structure C19H27O5S.NA.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E1CR8487EN chemically known as androst-5-en-17-one, 3.beta.-hydroxy-, hydrogen sulfate, sodium salt, dihydrate, but more commonly known as prasterone sodium sulfate, which bears US NIH Compound Identifier 14193. European Medicines Agency schedules Prasterone sodium sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04010MIG.

Most nations, for tariff and trade purposes, schedule prasterone sodium sulfate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C.[NA+].

UNSPSC 51182064 Prasterone sodium sulfate is a Commodity code covering a specific pharmaceutical ingredient supplied through state and local cooperative purchasing alliances for distribution across government healthcare facilities. State and local procurement under this code occurs through multi-state cooperative vehicles rather than individual agency RFPs; issuing bodies are state departments of administration and their procurement offices administering cooperative purchasing arrangements that serve participating states, counties, and local government healthcare systems. The scope centers on manufacturing and supplying generic pharmaceuticals and over-the-counter products meeting FDA cGMP certification and Drug Supply Chain Security Act compliance, with vendors required to maintain authorized wholesaler relationships, provide products under specific pricing models, and deliver comprehensive product data including NDC codes, SKUs, and packaging specifications.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted a Request for Proposal (S1070000015802) on January 20, 2026 seeking manufacturers of generic multi-source pharmaceuticals and OTC products for participating state and local facilities across Minnesota, Oregon, and other member jurisdictions. The RFP has a proposal due date of March 26, 2026, with questions due by February 18, 2026; awarded contracts will become effective July 1, 2026 and run for two years with optional extensions. Evaluation emphasizes price competitiveness (75 percent), with secondary weighting on fixed pricing (10 percent), EDI capability (5 percent), compliance with administrative fee data format (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability coverage of $5,000,000, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and supply products through one of three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, or Morris & Dickson Co., LLC.